DHG Pharmaceutical JSCSTC:DHG 77 ROA % is 24.24% as of Mar. 2026, which is 46% above its 10-year median of 16.57. GuruFocus rates STC:DHG with a GF Score™ of 77/100 and a GF Value™ of ₫113,344.20 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 94.63% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. DHG Pharmaceutical JSC's annualizedNet Income for the quarter that ended in Mar. 2026 was ₫1,262,709 Mil.
DHG Pharmaceutical JSC's average Total Assets over the quarter that ended in Mar. 2026 was ₫5,209,805 Mil. Therefore, DHG Pharmaceutical JSC's annualized ROA % for the quarter that ended in Mar. 2026 was 24.24%.
The historical rank and industry rank for DHG Pharmaceutical JSC's ROA % or its related term are showing as below:
STC:DHG'
s ROA % Range Over the Past 10 Years
Min: 12.91 Med: 16.57 Max: 20.21
Current: 17.36
During the past 13 years, DHG Pharmaceutical JSC's highest ROA % was 20.21%. The lowest was 12.91%. And the median was 16.57%.
STC:DHG's ROA % is ranked better than 94.63% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs STC:DHG: 17.36
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's ROA % distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
DHG Pharmaceutical JSC (STC:DHG) has a ROA % of 24.24% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on DHG Pharmaceutical JSC and its competitors. This is 46% above median its historical median of 16.57. Over the past decade, DHG Pharmaceutical JSC's ROA % has ranged from 12.91 to 20.21. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #54 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 5.4%.
Is DHG Pharmaceutical JSC's ROA % too high?
DHG Pharmaceutical JSC's current ROA % of 24.24% is 46% above median its 10-year median of 16.57. Over the past 10 years, this metric has ranged from a low of 12.91 to a high of 20.21. The Drug Manufacturers industry median ROA % is 2.69. DHG Pharmaceutical JSC's value of 24.24% is 802.8% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #54 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DHG Pharmaceutical JSC has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #54 out of 1006 companies for ROA %. This places DHG Pharmaceutical JSC in the top 5% of its industry — outperforming the majority of peers. The industry median ROA % is 2.69. DHG Pharmaceutical JSC's value of 24.24% is 802.8% above this benchmark. Historically, DHG Pharmaceutical JSC's own ROA % has ranged from 12.91 to 20.21 over the past decade. While the company's 10-year median is 16.57 vs. the industry median of 2.69, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current ROA % of 24.24% is 802.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current ROA % is 24.24%, which is 46% above median its own 10-year median of 16.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,344.20, compared to a current price of ₫94,700.00 — trading 16.4% below its estimated fair value. The current ROA % is 24.24%, which is 46% above median its 10-year median of 16.57 and 802.8% above the Drug Manufacturers industry median of 2.69. DHG Pharmaceutical JSC's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current ROA % is 24.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫94,700.00 is trading 16.4% below its estimated GF Value™ of ₫113,344.20.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
ROA %: 24.24% (46% above median its 10-year median of 16.57)
GF Value™: ₫113,344.20 vs. price of ₫94,700.00 (16.4% below fair value)
Industry Position: 802.8% above the Drug Manufacturers median (#54 of 1006)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
77GF Score
Get the complete analysis for STC:DHG
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
